Not all products or features are available in all markets.

  • Change country/language

    Looks like you’re in {} — you’re on the {} site.

    Cancel

    Country and language selected

    You are being redirected to the {} site. Products and services availability vary by country. Do you wish to continue?

    Continue
    Cancel
Press Releases

GE Announces Completion of BioPharma Sale to Danaher, Receives $20 Billion Net Cash Proceeds

March 31, 2020

BOSTON, Mass.—March 31, 2020—GE (NYSE:GE) announced today the completion of the sale of its BioPharma business to Danaher Corporation (NYSE:DHR) (“Danaher”) for approximately $20 billion of net proceeds.

 

GE Chairman and CEO H. Lawrence Culp, Jr., said, “Completing the sale of BioPharma represents a critical milestone on our multi-year transformation, fortifying our considerable sources to de-risk our balance sheet and continue to solidify our financial position. I am proud of the teams for completing this transaction amidst a great deal of global change. As we go forward, GE retains one of the world’s leading healthcare companies, using our global scale and technical leadership to deliver better outcomes and more capacity to a world striving for Precision Health.”

 

Under the terms of the transaction agreement, GE received a total consideration of $21.4 billion, including approximately $21 billion in cash as well as Danaher’s assumption of certain pension liabilities. After taking into account deal taxes, deal fees and factored receivable balances, net proceeds to GE totaled approximately $20 billion.

 

Caution Concerning Forward-Looking Statements
This document contains forward-looking statements – that is, statements related to future events that by their nature address matters that are, to different degrees, uncertain. For details on the uncertainties that may cause our actual future results to be materially different than those expressed in our forward-looking statements, see https://www.ge.com/investor-relations/important-forward-looking-statement-information, as well as our annual report on Form 10-K. We do not undertake to update our forward-looking statements.

 

About GE
GE (NYSE:GE) rises to the challenge of building a world that works. For more than 125 years, GE has invented the future of industry, and today the company’s dedicated team, leading technology, and global reach and capabilities help the world work more efficiently, reliably, and safely. GE’s people are diverse and dedicated, operating with the highest level of integrity and focus to fulfill GE’s mission and deliver for its customers. www.ge.com



GE’s Investor Relations website at www.ge.com/investor and our corporate blog at www.ge.com/reports and @GE_Reports on Twitter, as well as GE’s Facebook page and Twitter accounts, contain a significant amount of information about GE, including financial and other information for investors. GE encourages investors to visit these websites from time to time, as information is updated and new information is posted.

 

GE Investor Contact
Steve Winoker, 617.443.3400
swinoker@ge.com

 

GE Media Contact
Mary Kate Mullaney, 202.304.6514
marykate.nevin@ge.com

This press release is GE HealthCare historical archive material. Any reference in these materials to GE HealthCare products or their uses may not reflect current medical knowledge or up to date documentation for the products. Do not rely upon this release as a source of information on the safety or effectiveness of the products or on the contents of any product label or manual. Please refer to the current product documentation, including product labels and manuals, for current product information.

Copy article text Link copied to clipboard

About GE HealthCare Technologies Inc.

GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions that help clinicians tackle the world’s most complex diseases. Serving patients and providers for 130 years, GE HealthCare is delivering bold innovations designed for the next era of medicine across its Advanced Imaging Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics segments to help clinicians deliver more personalized, precise patient care. We are a $20.6 billion business with approximately 54,000 colleagues working to create a world where healthcare has no limits.

 

GE HealthCare is proud to be among 2026 Fortune World’s Most Admired Companies™.

 

Follow us on LinkedIn, FacebookInstagram, or visit our website for our latest news and perspectives